Skye Bioscience CEO Punit Dhillon joins Proactive's Natalie Stoberman to discuss the positive safety review for its Phase 2 clinical trial for its SBI-100 Ophthalmic Emulsion.
Dhillon said the trial's safety review committee has recommended that the trial continue without modification. Now, the company is preparing for Phase 3 recruitment for the third cohort of eight participants with dosing planned for March.
Proactive Investors US
+1 347-449-0879
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.44 |
| Daily Change: | -0.12 -2.16 |
| Daily Volume: | 235,606 |
| Market Cap: | US$165.050M |
February 26, 2024 January 09, 2024 December 11, 2023 November 28, 2023 | |
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE
Hillcrest Energy Technologies is a clean technology company developing high value, high performance power conversion technologies and digital control systems for next-generation powertrains and grid-connected renewable...
CLICK TO LEARN MORE
